Posted by Michael Wonder on 08 May 2018
Generic price competition for specialty drugs: too little, too late?
7 May 2018 - The case of generic imatinib demonstrates several potential barriers to effective generic price competition for specialty prescription drugs, including fewer market entrants, smaller-than-expected price reductions, shifts in prescribing toward more expensive brand-name treatments, and limited uptake of the generic product.
